CA3058407A1 - Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same - Google Patents

Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same Download PDF

Info

Publication number
CA3058407A1
CA3058407A1 CA3058407A CA3058407A CA3058407A1 CA 3058407 A1 CA3058407 A1 CA 3058407A1 CA 3058407 A CA3058407 A CA 3058407A CA 3058407 A CA3058407 A CA 3058407A CA 3058407 A1 CA3058407 A1 CA 3058407A1
Authority
CA
Canada
Prior art keywords
indirubin
solvent
dihydro
derivative
benzazepin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3058407A
Other languages
English (en)
French (fr)
Inventor
Bin Wu
Paul Boucher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Phosphorex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phosphorex Inc filed Critical Phosphorex Inc
Publication of CA3058407A1 publication Critical patent/CA3058407A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3058407A 2017-03-29 2018-03-29 Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same Pending CA3058407A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762478317P 2017-03-29 2017-03-29
US62/478,317 2017-03-29
PCT/US2018/025075 WO2018183631A1 (en) 2017-03-29 2018-03-29 Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same

Publications (1)

Publication Number Publication Date
CA3058407A1 true CA3058407A1 (en) 2018-10-04

Family

ID=63676834

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3058407A Pending CA3058407A1 (en) 2017-03-29 2018-03-29 Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same

Country Status (7)

Country Link
US (3) US20200016087A1 (https=)
EP (1) EP3600259A4 (https=)
JP (2) JP2020515598A (https=)
CN (2) CN115969814A (https=)
AU (1) AU2018244442A1 (https=)
CA (1) CA3058407A1 (https=)
WO (1) WO2018183631A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101855423B1 (ko) * 2017-04-18 2018-05-09 주식회사 씨케이바이오텍 인디루빈 유도체를 유효성분으로 포함하는 약학 조성물
MX2021012548A (es) * 2019-04-17 2023-01-05 Azora Therapeutics Inc Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel.
US12303490B2 (en) 2019-11-04 2025-05-20 Ck Regeon Inc. Compositions and methods for suppressing and/or treating neurodegenerative diseases and/or a clinical condition thereof
CN115175673A (zh) * 2020-02-26 2022-10-11 上海科技大学 双硫仑在抗冠状病毒中的应用
WO2022229985A1 (en) * 2021-04-29 2022-11-03 Jawaharlal Nehru Centre For Advanced Scientific Research Soluble analogues of 6bio thereof and implementation thereof
CN118317948A (zh) 2021-10-08 2024-07-09 阿佐拉治疗股份有限公司 芳烃受体激动剂的衍生物
CN114668744A (zh) * 2022-03-23 2022-06-28 成都大学 一种靛玉红固体脂质纳米粒及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1686988A1 (en) * 2003-10-28 2006-08-09 The Rockefeller University Indirubin-type compounds, compositions, and methods for their use
WO2012012616A1 (en) * 2010-07-21 2012-01-26 Patty-Fu Giles Photoactive vitamin nanoparticles for the treatment of chronic wounds
WO2012135813A1 (en) * 2011-03-31 2012-10-04 University Of Rochester Methods and compositions for mesenchymal stem cell proliferation
US9707186B2 (en) * 2012-02-21 2017-07-18 Amrita Vishwa Vidyapeetham Core-shell particle formulation for delivering multiple therapeutic agents
WO2013124867A1 (en) * 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
ES2685743T3 (es) * 2012-02-29 2018-10-11 Merck Patent Gmbh Procedimiento para la fabricación de nanopartículas cargadas con principio activo
EP2863897B1 (en) * 2012-06-21 2019-06-19 Phosphorex Inc. Nanoparticles of indirubin, derivatives thereof and methods of making and using same
WO2014152451A2 (en) * 2013-03-14 2014-09-25 University Of Rochester Compositions and methods for controlled localized delivery of bone forming therapeutic agents
CN103550206B (zh) * 2013-10-23 2015-11-25 重庆市中药研究院 一种白藜芦醇靛玉红组合药物、缓释微囊剂及其应用
EP2878312A1 (en) * 2013-12-02 2015-06-03 Albert-Ludwigs-Universität Freiburg Reversible PEGylation of nanocarriers
JP2017500343A (ja) * 2013-12-20 2017-01-05 フォスフォレックス，インコーポレーテッド インジルビン固体分散体組成物
WO2016197262A1 (en) * 2015-06-12 2016-12-15 Bayer Pharma Aktiengesellschaft Process for the preparation of porous microparticles
JP2018523702A (ja) * 2015-08-17 2018-08-23 フォスフォレックス，インコーポレイテッド 分解性ポリマーの極小ナノ粒子

Also Published As

Publication number Publication date
CN110709066A (zh) 2020-01-17
WO2018183631A1 (en) 2018-10-04
JP2020515598A (ja) 2020-05-28
US20230100193A1 (en) 2023-03-30
US20200016087A1 (en) 2020-01-16
WO2018183631A8 (en) 2019-08-15
EP3600259A4 (en) 2020-11-25
AU2018244442A1 (en) 2019-10-24
US20200383931A1 (en) 2020-12-10
EP3600259A1 (en) 2020-02-05
JP2023040147A (ja) 2023-03-22
CN115969814A (zh) 2023-04-18

Similar Documents

Publication Publication Date Title
US20230100193A1 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
EP1658053B1 (en) Novel compositions of sildenafil free base
JP2009507925A (ja) ナノ粒子タダラフィル製剤
JP2020517732A (ja) Ｈｓｐ９０阻害剤の経口製剤及び関連する方法
JP2005529911A (ja) ナノ粒子ナイスタチン製剤
MX2007015309A (es) Formulaciones de mesilato de imatinib en nanoparticulas.
KR20080105114A (ko) 나노입자형 카르베디롤 제제
MX2007008212A (es) Formulaciones de candesartan en nanoparticulas.
US10675350B2 (en) Nanoparticles of indirubin, derivatives thereof and methods of making and using same
JP2022538909A (ja) Ｃａｒ－ｔ細胞療法のための脂質－フルオレセイン結合体の設計および効率的合成の方法
EP3843705B1 (en) Preparation of nanosuspension comprising nanocrystals of active pharmaceutical ingredients with little or no stabilizing agents
JP5288791B2 (ja) 難水溶性物質含有微細化組成物
CN110384803B (zh) 一种大环主体分子作为药物增溶剂的应用
US20080213385A1 (en) Formulations for 7- (T-Butoxy) Iminomethyl Camptothecin
US20230414759A1 (en) Novel cyclic peptides based on nanobiostructural control, peptidesomes with core/shell structure comprising same, and uses thereof
CN118766866A (zh) 改善治疗剂的溶解度和生物利用度的方法
WO2024211881A1 (en) Rimegepant suspension

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230329

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240917

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20241002

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20251002

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251229